Health and Fitness Health and Fitness
Mon, November 28, 2011
Sun, November 27, 2011
Fri, November 25, 2011
Thu, November 24, 2011
Wed, November 23, 2011
[ Wed, Nov 23rd 2011 ] - Market Wire
00 a.m. EST
Tue, November 22, 2011
[ Tue, Nov 22nd 2011 ] - Market Wire
BD Board Increases Dividend
Mon, November 21, 2011
Sun, November 20, 2011
Fri, November 18, 2011
Thu, November 17, 2011
Wed, November 16, 2011
Tue, November 15, 2011
Mon, November 14, 2011
[ Mon, Nov 14th 2011 ] - Market Wire
30 AM Eastern Time
Sun, November 13, 2011

Medivation Names Sarah Noonberg Vice President of Clinical Development


//health-fitness.news-articles.net/content/2011/ .. berg-vice-president-of-clinical-development.html
Published in Health and Fitness on Thursday, November 17th 2011 at 13:19 GMT by Market Wire   Print publication without navigation


November 17, 2011 16:10 ET

Medivation Names Sarah Noonberg Vice President of Clinical Development

SAN FRANCISCO, CA--(Marketwire - Nov 17, 2011) - Medivation, Inc. (NASDAQ: [ MDVN ]) today announced that Sarah Noonberg, M.D., Ph.D. has been promoted to vice president of clinical development. Dr. Noonberg joined Medivation in 2007.

"This promotion is a reflection of Sarah's significant contributions to Medivation," said Lynn Seely, M.D., chief medical officer of Medivation. "Sarah will play a critical leadership role in our clinical organization as we work to advance new molecules into the clinic to support Medivation's planned pipeline growth."

Prior to joining Medivation, Dr. Noonberg held clinical positions of increasing seniority at Chiron Corporation, where she led the late phase clinical development of multiple compounds in infectious disease and pulmonary indications. Since joining Medivation in 2007, she has successfully led studies in all phases of development. Dr. Noonberg earned her M.D. at the University of California, San Francisco, her Ph.D. in Bioengineering at the University of California, Berkeley and her B.S. at Dartmouth College. Dr. Noonberg is a board-certified internist and completed her residency at the Johns Hopkins Hospital.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer and mild-to-moderate Alzheimer's disease. For more information, please visit us at [ www.medivation.com ].



Publication Contributing Sources